Clinical Research
If you are a referring physician or optometrist and believe a patient may be an appropriate candidate for clinical research, please indicate one of the following trials in your referral.
Below is a list of studies that are currently enrolling participants.
ADARx Pharmaceuticals
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Regeneneron Pharmaceuticals
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study Of The Efficacy, Safety, And Tolerability Of Subcutaneously Administered Pozelimab In Combination With Cemdisiran Or Cemdisiran Alone In Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration (SIENNA)
Kriya Therapeutics
A Multicenter, OBSERVational Study in PatiEnts with Geographic Atrophy Secondary to Age-related Macular Degeneration (OBSERVE)
A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector In AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)
AbbVie Corp.
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
To see our IBC meeting minutes click below.
06/18/2025
06/20/2025
08/20/2025
09/12/2025
04/05/2026